The clinical significance and treatment strategies for minimal acute rejection (grade A1), the most common form of acute rejection (AR), remain controversial. In this retrospective single-center cohort study of 441 lung transplant recipients, we formally evaluate the association between minimal AR and chronic lung allograft dysfunction (CLAD) and test a novel hypothesis using bronchoalveolar lavage (BAL) CXCL9 concentration during minimal AR as a biomarker of subsequent CLAD development. In univariable and multivariable models adjusted for all histopathologic injury patterns, minimal AR was not associated with CLAD development. However, minimal AR with elevated BAL CXCL9 concentrations markedly increased CLAD risk in a dose-response manner. Minimal AR with CXCL9 concentrations greater than the 25th, 50th, and 75th percentile had adjusted hazard ratios (HRs) for CLAD of 1.1 (95% confidence interval [CI] 0.8-1.6), 1.6 (95% CI 1.1-2.3), and 2.2 (95% CI 1.4-3.4), respectively. Thus we demonstrate the utility of BAL CXCL9 measurement as a prognostic biomarker that allows discrimination of recipients at increased risk of CLAD development after minimal AR. BAL CXCL9 measurement during transbronchial biopsies may provide clinically useful prognostic data and guide treatment decisions for this common form of AR, as a possible strategy to minimize CLAD development.
The clinical significance and treatment strategies for minimal acute rejection (grade A1), the most common form of acute rejection (AR), remain controversial. In this retrospective single-center cohort study of 441 lung transplant recipients, we formally evaluate the association between minimal AR and chronic lung allograft dysfunction (CLAD) and test a novel hypothesis using bronchoalveolar lavage (BAL) CXCL9 concentration during minimal AR as a biomarker of subsequent CLAD development. In univariable and multivariable models adjusted for all histopathologic injury patterns, minimal AR was not associated with CLAD development. However, minimal AR with elevated BAL CXCL9 concentrations markedly increased CLAD risk in a dose-response manner. Minimal AR with CXCL9 concentrations greater than the 25th, 50th, and 75th percentile had adjusted hazard ratios (HRs) for CLAD of 1.1 (95% confidence interval [CI] 0.8-1.6), 1.6 (95% CI 1.1-2.3), and 2.2 (95% CI 1.4-3.4), respectively. Thus we demonstrate the utility of BAL CXCL9 measurement as a prognostic biomarker that allows discrimination of recipients at increased risk of CLAD development after minimal AR. BAL CXCL9 measurement during transbronchial biopsies may provide clinically useful prognostic data and guide treatment decisions for this common form of AR, as a possible strategy to minimize CLAD development.
Introduction
Chronic lung allograft dysfunction (CLAD) is the leading cause of death after the first year and the major obstacle to improved long-term survival after lung transplantation (1) . Because there are no known effective therapies for CLAD, a crucial aspect of posttransplantation management is the identification, avoidance, and treatment of known risk factors for CLAD. Acute rejection (AR) remains one of the most well-studied risk factors for CLAD development. Previous studies have demonstrated a consistent association between higher grade (≥A2) acute rejection (AR) and CLAD (2) (3) (4) (5) . However, the clinical significance and optimal treatment of minimal AR (grade A1), the most common form of acute rejection, have remained controversial.
The 2006 revised working formulation for the grading of lung allograft AR is based on the presence of perivascular and interstitial mononuclear infiltrates: A0 ("no AR"); A1 ("minimal AR") -scattered, infrequent perivascular mononuclear infiltrate; A2 ("mild AR") -more frequent perivascular mononuclear infiltrate readily recognizable at low magnification; A3 ("moderate AR") -cuffing of venules and arterioles by dense perivascular mononuclear cell infiltrate; and A4 ("severe AR") -diffuse perivascular, interstitial, and air-space mononuclear cell infiltrate with alveolar pneumocyte damage and endothelitis (6) . Minimal AR was traditionally considered a benign pathologic finding without significant clinical sequelae (7, 8) . However, more recent studies have challenged this presumption by reporting increased CLAD risk after minimal AR (9, 10) . Furthermore, the optimal treatment of A1 rejection, including the need for augmented steroids, remains unclear. CXCL9 (MIG), CXCL10 (IP10), and CXCL11 (ITAC) are glutamic acid-leucine-arginine (ELR) negative CXC chemokines that are induced by interferon-c and signals through a G protein-coupled receptor, CXCR3. These chemokines are potent chemoattractants for type I immune response mononuclear cells (e.g. activated T cells and natural killer [NK] cells) (11) (12) (13) . In animal models, we and others have demonstrated that all three chemokines and their shared receptor parallel the grade of AR as well as CLAD (11, 12) . Of interest, CXCL9 expression was a magnitude of order greater than CXCL10 and CXCL11 expression during AR and CLAD (11, 12) . In vivo neutralization of CXCL9, with or without concurrent immunosuppressive agents, led to profound attenuation of AR as well as CLAD development (11, 12) . In addition, we have demonstrated elevation of bronchoalveolar lavage (BAL) CXCR3 chemokines during higher grade (≥A2) AR among human lung transplant recipients, as well as the utility of serial BAL CXCR3 measurements posttransplantation to predict CLAD development (5).
The current study extends these findings by formally evaluating the association between minimal AR and CLAD risk, an association that has remained controversial. Furthermore, we evaluate the novel use of BAL CXCR3 chemokine measurement at the time of minimal AR as a prognostic marker of subsequent CLAD risk. Based on our human data as well our animal studies (5, 11, 12) , we hypothesized that increased expression of CXCL9 in bronchoalveolar lavage fluid (BALF) during minimal AR, would increase the risk of subsequent CLAD development and have prognostic value as a biomarker of CLAD risk.
Materials and Methods
With institutional review board approval, we conducted a retrospective cohort study of patients who received lung transplantation at University of California Los Angeles (UCLA) between January 1, 2000 and December 31, 2010. Lung transplant recipients received a surveillance bronchoscopy with BAL and transbronchial biopsy (TBBX) at 1, 3, 6, and 12 months posttransplantation, as well as during episodes of clinical deterioration. Biopsies were interpreted by one of three pulmonary pathologists according to the International Multidisciplinary Consensus Statement on Idiopathic Interstitial Pneumonias (organizing pneumonia [OP] , diffuse alveolar damage [DAD], ≥A2 (14) , and the International Society for Heart and Lung Transplantation criteria (acute rejection [AR] and lymphocytic bronchiolitis [LB]) (6, 15) . TBBXs with no histopathologic evidence of allograft injury were considered "healthy."
Immunosuppression, antimicrobial prophylaxis, and treatment of acute rejection were administered in accordance with UCLA protocol as described previously (16) . Higher grade (≥A2) AR was treated with intravenous methylprednisolone, 500 mg, for 3 days followed by a prednisone taper from 0.5 mg/kg. Minimal AR was treated with a prednisone taper from 0.5 mg/kg without the methylprednisolone pulse. Treatment for DAD and OP was by with the discretion of the transplant pulmonologist and included methylprednisolone, intravenous immunoglobulin (IVIG), plasmapheresis, basiliximab, anti-thymocyte globulin (ATG), or no treatment. Spirometry was performed serially on at least a quarterly basis. CLAD was defined as a sustained 20% drop in the forced expiratory volume in 1 second (FEV1) from the average of the two best posttransplantation FEV1 measurements (3, 17) . In a subset analysis of double-lung transplant recipients, CLAD was further categorized as restrictive allograft syndrome (RAS)/restrictive CLAD (RCLAD) or bronchiolitis obliterans syndrome (BOS)/obstructive CLAD (OCLAD). RAS/RCLAD was defined as forced vital capacity (FVC)/FVC baseline >0.2 and chest computed tomography (CT) showing pleural/septal thickening, interstitial reticulation, or architectural distortion (18, 19) . Recipients with CLAD who did not fulfill RAS/RCLAD criteria were considered to have the BOS/OCLAD phenotype. Those who did not have a chest CT within 3 months of CLAD diagnosis were excluded from this subset analysis.
Recipients consented, with institutional review board approval, to the collection of BALF for research purposes. At the time of the bronchoscopies, three 60 mL aliquots of isotonic saline were instilled into the sub-segmental bronchus in the lingula, right middle lobe, or area of interest, and pooled. The supernatant was collected and stored unconcentrated at À80°C after centrifugation. BALF CXCR3 chemokine concentrations (CXCL9, CXCL10, and CXCL11) were measured using Luminex bead assays (Millipore, Billerica, MA).
To evaluate the effect of minimal AR on CLAD risk, univariable proportional hazards models for time to CLAD were constructed with cumulative time-dependent counts for minimal AR. This cumulative variable started at a value of 0 for all recipients. At the first episode of minimal AR, this variable increased from 0 to 1, and increased again from 1 to 2 at the second episode of minimal AR. The multivariable model was adjusted for the other known histopathologic predictors of allograft injury (DAD, OP, LB, and AR ≥A2) using cumulative time-dependent counts. To determine the impact of BALF CXCL9 elevation during minimal AR on subsequent CLAD risk, a time-dependent cumulative variable for minimal AR was created using quartiles of CXCL9 concentrations observed during AR. For example, using the first quartile cutoff, the "A1 + CXCL9 25th" variable would increase from 0 to 1 at the first episode of minimal AR, with BALF CXCL9 concentration greater than the 25th percentile. At the second episode of "A1 + CXCL9 25th," the variable would increase from 1 to 2. Univariable and multivariable models for CLAD were constructed using these "A1 + CXCL9" variables; multivariable models were adjusted for the other histopathologic injury patterns. Receiver-operating characteristic (OC) curves for CLAD development within 18 months of minimal AR were created for CXCL9, CXCL10, and CXCL11, as well as for their principal component (PC = 0.491 log CXCL9 + 0.521 log CXCL10 + 0.273 log CXCL11).
Results
The study cohort consisted of 441 lung transplant recipients with 1892 bronchoscopies with TBBXs in total. There were 114 biopsies (6%), from 96 recipients with DAD, 170 biopsies (9%) from 118 recipients with OP, 565 biopsies (30%) from 278 recipients with LB, and 393 biopsies (21%) from 232 recipients with AR. Among the AR biopsies, 198 (50%) were graded A1, 129 (33%) A2, 63 (16%) A3, and 3 (1%) A4. There were 303 biopsies that had concurrent injury patterns. AR occurred most frequently with LB (n = 193), followed by OP (n = 45) and DAD (n = 25). Biopsies without histopathology were classified as "healthy" biopsies (n = 842, 45%).
Clinical characteristics of recipients who developed grade A1 versus grade ≥A2 rejection were generally similar, including age at transplantation, gender, race, native disease, transplant type, and induction immunosuppression (Table 1) . A total of 207 recipients (47%) developed CLAD during the follow-up time. The average number of surveillance TBBXs was similar between recipients who developed CLAD compared with those who did not: 2.9 versus 2.8 (p = 0.66), respectively. There were slightly more nonsurveillance TBBXs among recipients who developed CLAD compared with those who did not (2.3 vs. 2.0; p = 0.057), respectively. Stratification of the acute rejection biopsies by clinical indication showed a similar frequency of grade A1 and A2, but a higher frequency of ≥A3 rejection for nonsurveillance compared with surveillance biopsies (6% vs. 2%; p = 0.001), respectively ( Table 2 ). The median time to CLAD was shorter for recipients with at least one episode of A1 rejection compared to those with no episodes of A1 rejection (1.8 vs. 2.6 years; p < 0.001), respectively. The median censoring time did not differ significantly between recipients with A1 rejection compared to those without (3.5 vs. 4.1 years; p = 0.18), respectively.
Risk of CLAD after acute rejection
To assess the impact of AR on CLAD risk, univariable and multivariable Cox models for CLAD were constructed with time-dependent cumulative counts for AR (grade A1, ≥A2, and ≥A3), as well as the other histopathologic injury patterns (DAD, OP, and LB). In univariable analysis, DAD (hazard ratio [HR] 1.6, 95% confidence interval [CI] 1.2-2.3), OP (HR 1.5, 95% CI 1.1-2.1), AR ≥A2 (HR 1.4, 95% CI 1.04-1.9), and AR ≥A3 (HR 2.1, 95% CI 1.4-3.0) were all associated with increased CLAD risk ( Table 3) . Minimal AR and LB were not associated with CLAD development. The three AR variables (AR = A1, AR ≥A2, and AR ≥A3) were then evaluated in multivariable models adjusted for other injury patterns. In the multivariable model including DAD, OP, LB, and AR ≥A2, we found that DAD (HR 1.4, 95% CI 1.02-2.0), and AR ≥A2 (HR 1.4, 95% CI 1.1-1.9) both predicted CLAD development, whereas OP and LB did not. Similarly, in the model including DAD, OP, LB, and AR ≥A3, we found that DAD (HR 1.7, 95% CI 1.2-2.4) and AR ≥A3 (HR 2.1, 95% CI 1.4-3.1) predicted CLAD, whereas OP and LB did not. Minimal AR was not a significant predictor of CLAD in multivariable models adjusted for other injury patterns. In addition, we found no association between episodes of recurrent minimal AR and CLAD (data not shown).
To determine the importance of clinical indication for the biopsy on CLAD risk, episodes of minimal AR were categorized as surveillance or nonsurveillance. Univariable and multivariable Cox models for CLAD were constructed with time-dependent cumulative counts for surveillance and nonsurveillance episodes of minimal AR (Table 4) . In univariable models, nonsurveillance minimal AR was associated with CLAD risk (HR 1.5, 95% CI 1.02-2.2), whereas surveillance minimal AR was not. In the multivariable model adjusted for other injury patterns, both surveillance and nonsurveillance minimal AR had no effect on CLAD risk.
BALF CXCR3 chemokines concentrations during acute rejection
We hypothesized that BALF CXCR3 ligands would be elevated during AR and that episodes of higher grade AR would have higher CXCR3 concentrations, reflecting the increased risk of CLAD development. We evaluated 1281 BALF samples from 382 recipients in total. There were 144 samples from 113 recipients with AR = A1, 119 samples from 93 recipients with AR ≥A2, and 33 samples from 28 recipients with AR ≥A3. A total of 589 samples from 305 recipients did not have any histopathology 0  1490  79  862  81  628  77  1  198  11  109  10  89  11  2  129  7  76  7  53  6  3  6 3  3  2 0  2  4 3  5  4  3  0  0  0  3  0 AR, Acute rejection; n, number of samples; %, percent of samples.
and were considered "healthy" samples. Median BALF CXCL9, CXCL10, and CXCL11 concentrations were higher during all episodes of acute rejection compared with "healthy" biopsies (Table 5) . CXCL9, CXCL10, and CXCL11 concentrations for AR = A1 versus "healthy" biopsies were as follows: 872 versus 335 (p = 0.01), 275 versus 135 (p < 0.001), and 71 versus 62 pg/mL (p = 0.06), respectively. There was a nonsignificant trend toward higher BALF CXCR3 ligand concentrations during episodes of higher grade AR. Median CXCL9 concentrations for AR ≥A2 versus AR ≥A3 were 1220 versus 2775 pg/mL, respectively. Similarly, median CXCL10 and CXCL11 concentrations for AR ≥A2 versus AR ≥A3 were 241 versus 433 and 67 versus 78 pg/mL, respectively.
Similar to prior animal models of rejection by our group, the increase in BAL expression during AR was greatest for CXCL9, compared with CXCL10 and CXCL11. During minimal AR, BAL concentrations increased threefold for CXCL9, twofold for CXCL10, and just greater than onefold for CXCL11, compared with healthy biopsies (Table 5) . Thus for all subsequent analysis, we focused on the prognostic significance of BAL CXCL9 concentrations. The 25th, 50th, , and 75th percentiles of CXCL9 during AR were 309 pg/mL, 915 pg/mL, and 3001 pg/ mL, respectively, and right skewed (1.3) with a standard deviation of 2973.
Impact of BALF CXCL9 during minimal AR on CLAD risk We found no association between episodes of minimal AR and CLAD development in multivariable Cox models adjusted for the other injury patterns. However, we hypothesized that minimal AR with high BALF CXCL9 concentrations would be associated with higher CLAD risk. To test this hypothesis, time-dependent cumulative variables for minimal AR were created using quartiles of BALF CXCL9 concentrations. These variables were a cumulative count of A1 rejection only where the CXCL9 concentration was greater than the specified quartile-cutoff. Multivariable models adjusted for other histopathologic injury patterns demonstrated a strong association between CXCL9 concentrations during minimal AR and subsequent CLAD risk. The HR for an episode of minimal AR with CXCL9 concentration greater than the 25th percentile was 1.1 (95% CI 0.8-1.6). The HR increased to 1.6 (95% CI 1.1-2.3) and 2.2 (95% CI 1.4-3.4) for CXCL9 concentrations greater than the 50th and 75th percentiles, respectively (Table 6 ). In these multivariable models, DAD and AR ≥A2 were also significant predictors off CLAD; however, the HRs for minimal AR with CXCL9 greater than the 75th percentile surpassed the HRs for DAD (1.5, 95% CI 1.05-2.1) and AR ≥ A2 (1.4, 95% CI 1.05-1.9).
We compared the prognostic performance of the three CXCR3 chemokines during minimal AR, using ROC analysis to evaluate CLAD development within a year and a half of the biopsy. As depicted in Figure 1 , the prognostic performance of CXCL9 to predict CLAD development was superior to CXCL10 and CXCL11 with areas under the curve (AUCs) of 0.76, 0.73, and 0.67, respectively. The CXCL9 optimum cutoff that maximized the correct classification rate was 3522 pg/ mL. This cutoff was associated with a high negative predictive value (NPV), but low positive predictive value (PPV) for subsequent CLAD development. The sensitivity, specificity, PPV, and NPV for CLAD development within a year and a half of the biopsy were as follows: 40%, 95%, 33%, and 86%, respectively. Thus low BAL CXCL9 effectively identified episodes of minimal AR with low risk of developing CLAD. With an NPV of 86%, only 14% of recipients who had minimal AR with CXCL9 <3522 pg/mL developed CLAD in the next 18 months. On the other hand, 33% of recipients who had minimal AR with CXCL9 ≥3522 pg/mL developed CLAD in the next 18 months. The first principal component of the three chemokines did not significantly improve the prognostic performance. The first PC was calculated as PC = 0.491 9 log(CXCL9) + 0.521 9 log (CXCL10) + 0.273 9 log(CXCL11), with an AUC for 18-month CLAD development of 0.78.
Impact of clinical indication for bronchoscopy
We then explored the association between high BAL CXCL9 concentrations and subsequent CLAD development among asymptomatic and symptomatic episodes of minimal AR. Asymptomatic episodes of minimal AR observed during "surveillance" transbronchial biopsies demonstrated a similar association between higher CXCL9 concentrations and higher CLAD risk. In the multivariable model adjusted for other injury patterns, the HR for CLAD for an episode of asymptomatic minimal AR with CXCL9 concentrations greater than optimum cutoff (3522 pg/mL) was 3.9 (1.7-8.9), Table 7 . Similarly, higher CXCL9 concentrations during symptomatic minimal AR observed during "non-surveillance" transbronchial biopsies were also associated with higher CLAD risk. The adjusted HR for CLAD for an episode of symptomatic minimal AR with CXCL9 concentrations greater than the optimum cutoff was 4.0 (2.1-7.7). DAD and AR ≥A2 were also significant predictors of CLAD in this model, but the HRs for both nonsurveillance and surveillance A1 with elevated CXCL9 surpassed the HRs for DAD (HR 1.6, 95% CI 1.1-2.2) and AR ≥A2 (HR 1.4, 95% CI 1.03-1.9).
Risk of BOS/OCLAD and RAS/RCLAD after minimal AR
In a subset analysis of double-lung transplant recipients, we evaluated the association between BAL CXCL9 elevation during minimal AR and the phenotypes of CLAD: BOS/OCLAD and RAS/RCLAD. Thirty-three (31%) of 106 double-lung transplant recipients who developed CLAD were classified as RAS/RCLAD, whereas the remaining 73 (69%) were classified as BOS/OCLAD. Minimal A1 with CXCL9 concentrations greater than the optimum cutoff (3522 pg/mL) was associated with both BOS/OCLAD and RAS/RCLAD development with HRs: 4.5 (95% CI 1.7-11.6) and 3.7 (95% CI 1.1-12.3), respectively ( Table 8) .
None of the allograft injury patterns (without consideration of CXCL9) increased BOS/OCLAD or RAS/RCLAD risk. However, this subset analysis of double lung transplant recipients with chest CT scans within 3 months of CLAD diagnosis was limited by sample size (n = 253).
Impact of BALF CXCL9 during other allograft injury patterns
Finally,, we extended our analysis to evaluate the impact of BAL CXCL9 elevation during any allograft injury pattern (DAD, OP, LB, or AR ≥1) on the risk of subsequent CLAD development. A time-dependent cumulative count was created for both "surveillance" and "nonsurveillance" allograft injury patterns with CXCL9 concentration greater than the optimum cutoff (3522 pg/mL). In the multivariable model adjusted for the allograft injuries, CXCL9 elevation during both "surveillance" and "nonsurveillance" allograft injuries were associated with CLAD: HRs 5.2 (95% CI 1.6-17.1) and 5.4 (95% CI 2.5-11.5), respectively ( Table 9) . DAD was the only injury pattern associated with CLAD in the multivariable model (HR 2.2, 95% CI 1.4-3.4). 
Discussion
CLAD remains the major factor limiting survival after lung transplantation, affecting 48% of recipients by 5 years and imparting a 3-year mortality >50% after its onset (20) . Prior studies have demonstrated a consistent association between higher grade (≥A2) acute rejection and CLAD (3, 4, 21) . However, the clinical significance and treatment strategies for minimal acute rejection (grade A1), the most common form of acute rejection, remains controversial. In this analysis, we sought to formally evaluate the association between minimal AR and CLAD development and test a novel hypothesis using BAL CXCL9 concentration during minimal AR as a biomarker of subsequent CLAD development. We demonstrate for the first time the utility of BAL CXCL9 measurement as a prognostic biomarker that allows discrimination of CLAD risk after minimal AR. Low BAL CXCL9 effectively identified episodes of minimal AR with low risk of subsequent CLAD development. With an NPV of 86%, only 14% of recipients who had minimal AR with CXCL9 <3522 pg/ mL developed CLAD in the next 18 months. On the other hand, 33% of recipients who had minimal AR with CXCL9 ≥75th percentile developed CLAD in the next 18 months. Multivariable Cox models adjusted for other histopathologic injury patterns confirms the prognostic importance of high BAL CXCL9 (≥3522 pg/mL) with an adjusted HR for CLAD of 4.0 (95% CI 2.4-6.8), surpassing the HRs of all histopathologic injury patterns. These findings suggest that BAL CXCL9 measurement at the time of TBBXs provides clinically useful prognostic data and may potentially guide treatment of this common form of AR, as a strategy to minimize subsequent CLAD development.
Prior studies have established a consistent association between high-grade AR (≥A2) and CLAD, but the association between minimal AR and CLAD, as well as the need for treatment of minimal AR, has been less clear. Minimal AR was traditionally regarded an innocuous finding without significant clinical sequelae (7, 8) , but recent studies have challenged this presumption. Hopkins et al. evaluated 1159 biopsies from 184 recipients and found that recurrent episodes of A1 rejection had higher CLAD risk compared to those with one or less A1 episodes: 68% versus 43%, respectively (p = 0.022) (9) . Another study of 259 recipients found that a single episode of A1 rejection was associated with a twofold increase in the risk of CLAD in multivariable modeling (10) . This study also showed that treatment of minimal AR decreased the risk of subsequent CLAD development. One important difference between these studies and our study was in the treatment of asymptomatic minimal AR. Although we routinely treated symptomatic and asymptomatic A1, the prior studies treated only symptomatic A1 with prednisone or methylprednisolone. This may have attenuated the association between minimal AR and CLAD in our study.
Furthermore, our work builds on these prior studies by utilizing a biomarker obtained at the time of biopsy to further characterize episodes of minimal AR in terms of its CLAD risk. In rodent models, our group previously demonstrated the key role of CXCL9/CXCR3 biology in the pathogenesis of AR (12) , through its recruitment of CXCR3-expressing mononuclear cells into the allograft. Furthermore, these models showed that the persistent elevation of CXCL9 in the allograft led to chronic rejection, whereas neutralization of CXCL9 attenuated its development (12) . Thus in this study we hypothesized that elevated BALF CXCL9 concentrations during minimal AR, would significantly increase the risk of subsequent CLAD development.
Overall, minimal AR was not associated with increased CLAD risk in univariable and multivariable models adjusted for other histopathologic injury patterns. However, minimal AR with elevated BAL CXCL9 concentrations markedly increased CLAD risk in a dose-response manner. A single episode of minimal AR with CXCL9 >25th, 50th, and 75th, percentiles had an HR for CLAD of 1.1, 1.7, and 2.3, respectively. This association between high BAL CXCL9 and CLAD risk remained valid for both symptomatic and asymptomatic episodes of minimal AR detected during routine surveillance bronchoscopies. Furthermore, this association between elevated CXCL9 and CLAD risk remained valid for other injury patterns, including higher grade AR, DAD, OP, and LB.
The major limitation of this study is the potential for confounding given the retrospective single-center design. For example, patients with clinical deterioration may have received more frequent biopsies leading to a higher incidence of allograft injury and higher BALF CXCR3 ligand concentrations. Multivariable adjustment for all known risk factors for CLAD (e.g. primary graft dysfunction, donor specific antibodies, community acquired respiratory viruses) was beyond the scope of this analysis. Adjustment for these known risk factors may have attenuated our results in multivariable models. TBBXs were interpreted by one of three pulmonary pathologists experienced in grading AR; however, several studies have demonstrated significant interobserver variability in the grading of TBBX specimens after lung transplantation (22, 23) , raising concerns about the reliability of the biopsy interpretations. Most importantly, treatments received for allograft injury were also not taken into account. At our institution, recipients routinely received augmented immunosuppression for AR but not for DAD, OP, or LB. Higher grade AR, was treated with intravenous solumedrol, 500 to 1000, mg for t3 days followed by a prednisone taper from 0.5 mg/kg. Minimal AR was treated with a prednisone taper from 0.5 mg/kg without the solumedrol pulse. Treatment for DAD, OP, and LB was by discretion of the transplant pulmonologist and included methylprednisolone, IVIG, plasmapheresis, basiliximab, ATG, or no treatment. This may have attenuated the CLAD risk associated with higher grade AR, DAD, and OP.
Despite these limitations, our results are unique in demonstrating the prognostic value of a biomarker concurrent with allograft injury, which outperforms the histopathologic finding from the biopsy. This finding may be particularly relevant for minimal AR, where the prognosis is strongly dependent on the biomarker measurement, and the need for treatment remains controversial. BAL CXCL9 concentration during minimal AR can discriminate between high-and low-risk injury and identify recipients who may benefit from more aggressive treatment. This study evaluated 1892 biopsies from 441 recipients and to our knowledge, is the largest study to evaluate CLAD risk after minimal AR, and the first study to examine the prognostic significance of BAL CXCL9 concentrations during minimal AR.
In summary, we demonstrate for the first time the utility of BAL CXCL9 measurement as a prognostic biomarker that allows discrimination of a recipient's CLAD risk after minimal AR, the most common form of AR. Overall, episodes of minimal AR, without consideration of BAL CXCL9, did not increase CLAD risk in multivariable models. However, we find a marked increase in CLAD risk for episodes of minimal AR with BAL CXCL9 elevation in a dose-response manner. This association between BAL CXCL9 and CLAD risk remained valid for both surveillance and non-surveillance episodes of minimal AR. These findings suggest that BAL CXCL9 measurement at the time of TBBXs provides clinically useful prognostic data and may potentially guide treatment of this common form of AR, as a strategy to minimize subsequent CLAD development.
